Skip Navigation LinksHome > May 2009 - Volume 4 - Issue 3 > Liver disease: the effects of HIV and antiretroviral therapy...
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e328329c602
Early treatment: Edited by Sean Emery and Andrew Phillips

Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation

Vogel, Martin; Rockstroh, Jürgen K

Collapse Box


Purpose of review: With the advent of highly active antiretroviral therapy (HAART), end-stage liver disease has emerged as a major cause of death in HIV and hepatitis-coinfected patients. With the recent change of guidelines recommending early HAART for the treatment of HIV in hepatitis B or C-coinfected patients, the question arises how these recommendations are substantiated by existing data. In the following review, we discuss current data on the effects of HAART in the context of concurrent hepatitis B and C infection.

Recent findings: Virologically successful HAART slows the progression of liver fibrosis and downregulates liver inflammation in hepatitis-coinfected patients. Indeed, cohort studies demonstrate a reduction in liver disease-related death events in HAART-treated patients. Moreover, the rate of immune reconstitution under HAART has been shown to determine the risk for future hepatic decompensation.

Summary: Early HAART clearly proves to be beneficial for hepatitis-coinfected patients, and concerns on an increased risk for drug-related liver injury should not be a reason to withhold HAART.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.